Literature DB >> 1714004

Proarrhythmic activity of intracoronary endothelin in dogs: relation to the site of administration and to changes in regional flow.

P Salvati1, S Chierchia, L Dho, R G Ferrario, P Parenti, G Vicedomini, C Patrono.   

Abstract

The endothelium-derived peptide, endothelin, has been shown to exert powerful constrictor activity in both isolated and in situ coronary arteries. Recent in vitro data on isolated cardiac myocytes suggest that the substance might also possess electrophysiologic properties. We investigated the possibility that endothelin (ET-1) may exert proarrhythmic effects when infused selectively in the coronary circulation of open-chest-anesthetized dogs. Animals were instrumented for the measurement of left anterior descending (LAD) or left circumflex (LCX) coronary artery blood flow, left systolic ventricular pressure (LSVP), dP/dtmax, mean arterial pressure (MAP), and epicardial electrocardiogram (ECG; three leads). Data were recorded during infusion (2 min) of saline (n = 5) or increasing doses of endothelin (5-80 pmol/kg) given selectively in either the LCX (n = 10) or the LAD (n = 10). When infused into the LCX, endothelin produced a dose-dependent decrease in flow (40 +/- 23% at 80 pmol/kg, mean +/- SD, p less than 0.01) with a concomitant increase in coronary resistance and a decrease in dP/dtmax and MAP. ECG changes typical of myocardial ischemia paralleled the decrease in flow and culminated in ventricular fibrillation at the highest dose (80% of dogs). Endothelin caused similar hemodynamic effects when infused in the LAD, but fatal arrhythmias occurred for lower doses and for little or no change in coronary blood flow. Thirty percent of the animals died at 10 and 60% died at 20 pmol/kg, doses that induced only a moderate decrease (8 +/- 7 and 21 +/- 12%, respectively) in LAD total blood flow. Ventricular tachycardia always preceded ventricular fibrillation and death.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1714004     DOI: 10.1097/00005344-199106000-00022

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  5 in total

1.  Endothelin-1 mediated inhibition of the acetylcholine-activated potassium current from rabbit isolated atrial cardiomyocytes.

Authors:  J P Spiers; E J Kelso; B J McDermott; C N Scholfield; B Silke
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

2.  Electrophysiological and haemodynamic effects of endothelin ETA and ETB receptors in normal and ischaemic working rabbit hearts.

Authors:  Christopher McCabe; Martin N Hicks; Kathleen A Kane; Cherry L Wainwright
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

3.  Role of endogenous endothelin in myocardial and coronary endothelial injury after ischaemia and reperfusion in rats: studies with bosentan, a mixed ETA-ETB antagonist.

Authors:  V Richard; N Kaeffer; M Hogie; C Tron; T Blanc; C Thuillez
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

4.  Impulse conduction and gap junctional remodelling by endothelin-1 in cultured neonatal rat ventricular myocytes.

Authors:  Y Reisner; G Meiry; N Zeevi-Levin; D Y Barac; I Reiter; Z Abassi; N Ziv; S Kostin; J Schaper; M R Rosen; O Binah
Journal:  J Cell Mol Med       Date:  2009-03       Impact factor: 5.310

Review 5.  Classic and Novel Biomarkers as Potential Predictors of Ventricular Arrhythmias and Sudden Cardiac Death.

Authors:  Zornitsa Shomanova; Bernhard Ohnewein; Christiane Schernthaner; Killian Höfer; Christian A Pogoda; Gerrit Frommeyer; Bernhard Wernly; Mathias C Brandt; Anna-Maria Dieplinger; Holger Reinecke; Uta C Hoppe; Bernhard Strohmer; Rudin Pistulli; Lukas J Motloch
Journal:  J Clin Med       Date:  2020-02-20       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.